Vivos Therapeutics, Inc., a company listed on The Nasdaq Stock Market, reported on July 10, 2024, that it has received approval from a Nasdaq Hearings Panel to continue its listing, contingent on demonstrating compliance with the stockholders' equity requirement by August 15, 2024. The company had previously been notified of non-compliance with Nasdaq's minimum equity requirement of $2.5 million as of March 31, 2024. Vivos Therapeutics addressed this issue by closing a $7.5 million equity private placement on June 10, 2024, and subsequently met with the Panel on June 27, 2024. The company is actively working to maintain compliance, exploring additional equity financing, and expects positive impacts on revenue and equity from a strategic marketing and distribution alliance. However, there is a risk of failing to maintain the required equity level, which could lead to delisting and materially affect the company's stock price and operations.

Vivos Therapeutics, Inc., a company listed on The Nasdaq Stock Market, reported on July 10, 2024, that it has received approval from a Nasdaq Hearings Panel to continue its listing, contingent on demonstrating compliance with the stockholders' equity requirement by August 15, 2024. The company had previously been notified of non-compliance with Nasdaq's minimum equity requirement of $2.5 million as of March 31, 2024. Vivos Therapeutics addressed this issue by closing a $7.5 million equity private placement on June 10, 2024, and subsequently met with the Panel on June 27, 2024. The company is actively working to maintain compliance, exploring additional equity financing, and expects positive impacts on revenue and equity from a strategic marketing and distribution alliance. However, there is a risk of failing to maintain the required equity level, which could lead to delisting and materially affect the company's stock price and operations.